Hemofilia A congénita con inhibidores e inducción de inmunotolerancia en niños y adolescentes jóvenes: ¿podría Brasil ser un ejemplo para otros países?

C.M. da Silva Pinto; L. Martins da Silva; F. Ferreira de Carvalho Jr

Ayuda

Hemofilia A congénita con inhibidores e inducción de inmunotolerancia en niños y adolescentes jóvenes: ¿podría Brasil ser un ejemplo para otros países?

C.M. da Silva Pinto ^[1] ; L. Martins da Silva ^[2] ; F. Ferreira de Carvalho Jr ^[2]
1. [1] Universidade Federal de São Paulo
  
  Universidade Federal de São Paulo
  
  Brasil
2. [2] Medical Affairs Department, Takeda Pharmaceuticals Brazil
Localización: Revista Hematología, ISSN 0329-0379, ISSN-e 2250-8309, Vol. 26, Nº. 1, 2022 (Ejemplar dedicado a: Enero - Abril 2022), págs. 1-10
Idioma: español
Títulos paralelos:
- Congenital hemophilia A with inhibitors and immune tolerance induction in children and young adolescents: could Brazil be an example for other countries?
Enlaces
- Texto completo (pdf)
Resumen
- Brazil has the third highest population of patients diagnosed with hemophilia A in the world and the first in Latin America. Factor VIII (FVIII) replacement prophylaxis is the standard of care currently recommended worldwide. However, about 30% of all patients with severe hemophilia A will develop neutralizing antibodies against FVIII, called inhibitors. The proposed aim of immune tolerance induction (ITI) therapy is to eradicate inhibitors, and sev-eral protocol variations are available. In Brazil, ITI treatment follows an escalating rationale, initiating with a low-dose scheme using FVIII 50 IU/kg, three times a week. When the absence of a decline in inhibitor titer with a low-dose regimen of at least 20%, in every six-month period after the beginning of ITI, is observed, it is recommended to initiate high-dose scheme using FVIII 100 IU/kg every day. About one third of all patients with hemophilia A are children and adolescents. Disease management in this population prompts different challenges, potentially leading to chronic and lifelong disabilities, and the age at first treatment also seems to act as a risk factor for inhibitor development. In this narrative review, the authors’ conclusion provides comprehensive knowledge regarding severe congenital hemophilia A with inhibitors (CHAWI) and ITI in children and adolescents, discussing different ITI protocols, with different outcomes, focusing on comparing Brazil's with other global guidelines.